Abstract
Background: Glioblastoma is a grade IV glioma tumor, and is the most frequent neoplasia in the central nervous system. Patients with glioblastoma have a very low overall survival rate and poor prognosis. Their major therapeutic challenges are the limited penetration of therapeutic agents through the blood-brain barrier, increased treatment resistance, and tumor heterogeneity. Case presentation: Anti-programmed cell death 1 (PD-1) immune checkpoint blockade-based therapy using pembrolizumab achieved good stability and non-recurrence in a Kurdish patient with highgrade glioblastoma who was refractory to first-line therapy. Conclusion: It appears that after the failure of routine and standard treatments in patients with glioblastoma, an immunotherapy-based therapeutic strategy is suitable for improving their clinical outcomes and creating antitumor effects.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
